Sponsors (47)
The bill clarifies which gene‑targeting drugs qualify as single‑source 'advanced drug products,' improving access and payment predictability for patients and providers but risking higher public costs and reduced competition if more high‑cost products receive protected treatment or if vague language causes disputes.
Patients with genetic or chronic conditions: gain clearer access to coverage and special handling for advanced gene‑targeting drugs because the bill clarifies which products qualify as single‑source 'advanced drug products'.
Medicare and Medicaid beneficiaries receiving gene‑targeted therapies: are likely to see more consistent application of single‑source rules, reducing billing uncertainty and unexpected cost‑sharing for expensive advanced therapies.
Hospitals and health systems: can better plan formularies and reimbursement expectations because the Secretary is required to apply the clarified definition when implementing §1192 requirements.
Taxpayers (and public insurance programs): could face higher costs if the clarification expands which high‑cost gene‑targeted drugs receive single‑source protections or special reimbursement treatment.
Patients and the market for therapies: competing manufacturers may face strengthened single‑source status for certain gene‑targeted products, which could limit competition and help keep prices high for those therapies.
Patients and providers: broad or vague wording (e.g., 'may modulate') could create ambiguity about which drugs qualify, producing administrative disputes and delays in coverage decisions for some patients.
Based on analysis of 2 sections of legislative text.
Adds an "advanced drug product" definition to the qualifying single source drug rule to include drugs using genetically targeted technologies that modulate genes or gene products.
Official title: To amend title XI of the Social Security Act to protect access to genetically targeted technologies.
Introduced February 27, 2025 by Don Davis · Last progress February 27, 2025
Modifies the federal definition used to identify a "qualifying single source drug" by adding a new category called an "advanced drug product." An "advanced drug product" is defined to include drugs that use a genetically targeted technology that can modulate (suppress, up‑regulate, or activate) a gene or its gene product. The change inserts a cross‑reference and a new definition into the Social Security Act provision governing qualifying single source drugs.